Pulmonary arterial hypertension (PAH) is a disease characterised by raised pulmonary vascular resistance. It has a poor prognosis typically resulting in progressive right ventricular failure and death. Treatment in PAH has advanced rapidly over the past decade with the use of Ca2+ channel blockers, prostanoids, endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors [ 1 x [1] Galie, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. Oct 2009; 30: 2493–2537 Crossref | PubMed | Scopus (2458) | Google Scholar See all References ] [1] . PAH often has an insidious onset, which means that diagnosis and treatment are usually not begun until the disease is advanced. Recent studies have looked at patients with less severe disease (World Health Organisation (WHO) class II), and have shown that early initiation of therapy can delay the progression of the disease [ 2 x [2] Galie, N., Rubin, L., Hoeper, M., Jansa, P., Al-Hiti, H., Meyer, G. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371: 2093–2100 Abstract | Full Text | Full Text PDF | PubMed | Scopus (645) | Google Scholar See all References ] [2] .